- Home
- YGMZ vs CMND Comparison
YGMZ vs CMND Comparison
Compare YGMZ & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YGMZ
- CMND
- Stock Information
- Founded
- YGMZ 2002
- CMND 2017
- Country
- YGMZ China
- CMND Canada
- Employees
- YGMZ N/A
- CMND N/A
- Industry
- YGMZ Transportation Services
- CMND Biotechnology: Pharmaceutical Preparations
- Sector
- YGMZ Consumer Discretionary
- CMND Health Care
- Exchange
- YGMZ Nasdaq
- CMND Nasdaq
- Market Cap
- YGMZ 7.0M
- CMND 7.5M
- IPO Year
- YGMZ 2020
- CMND N/A
- Fundamental
- Price
- YGMZ $0.86
- CMND $1.49
- Analyst Decision
- YGMZ
- CMND
- Analyst Count
- YGMZ 0
- CMND 0
- Target Price
- YGMZ N/A
- CMND N/A
- AVG Volume (30 Days)
- YGMZ 124.8K
- CMND 2.9M
- Earning Date
- YGMZ 01-01-0001
- CMND 01-28-2025
- Dividend Yield
- YGMZ N/A
- CMND N/A
- EPS Growth
- YGMZ N/A
- CMND N/A
- EPS
- YGMZ N/A
- CMND N/A
- Revenue
- YGMZ $55,805,416.00
- CMND N/A
- Revenue This Year
- YGMZ N/A
- CMND N/A
- Revenue Next Year
- YGMZ N/A
- CMND N/A
- P/E Ratio
- YGMZ N/A
- CMND N/A
- Revenue Growth
- YGMZ N/A
- CMND N/A
- 52 Week Low
- YGMZ $0.68
- CMND $0.92
- 52 Week High
- YGMZ $6.24
- CMND $2.30
- Technical
- Relative Strength Index (RSI)
- YGMZ 44.05
- CMND 52.63
- Support Level
- YGMZ $0.68
- CMND $1.41
- Resistance Level
- YGMZ $0.85
- CMND $1.62
- Average True Range (ATR)
- YGMZ 0.09
- CMND 0.13
- MACD
- YGMZ -0.01
- CMND 0.00
- Stochastic Oscillator
- YGMZ 40.23
- CMND 33.33
About YGMZ MingZhu Logistics Holdings Limited
MingZhu Logistics Holdings Ltd is a Holding company. Its business activities include trucking services and car owner services. Its segments are the trucking business, car owner services business, and liquor distribution business. It generates the majority of its revenue from the trucking segment.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.